Protective effects of miR-155-5p silencing on IFN-γ-induced apoptosis and inflammation in salivary gland epithelial cells

JINGLI ZHANG¹, LINGLING ZHU², HONG SHI¹ and HUIZHE ZHENG³,⁴

Departments of ¹Rheumatology and Immunology, ²Hematology and ³Pathology; ⁴Key Laboratory of Tumor Prevention and Treatment of Heilongjiang Province, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China

Received August 12, 2020; Accepted January 8, 2021

DOI: 10.3892/etm.2021.10314

Abstract. Previous studies have demonstrated that microRNAs (miRNAs/miRs) serve a vital role in the pathogenesis of Sjögren’s syndrome (SS). The present study aimed to investigate the role of miR-155-5p in SS and determine its underlying molecular mechanism. An inflammatory lesion model was established by stimulating salivary gland epithelial cells (SGECs) with interferon-γ (IFN-γ). The apoptosis of SGECs was measured by using flow cytometry. Levels of proinflammatory factors were detected by reverse transcription-quantitative PCR and ELISA, respectively. Immunofluorescence was used for p65 staining. Dual-luciferase reporter assay was performed to verify the interaction between miR-155-5p and arrestin β2 (ARRB2). The protein levels in the NF-κB signaling pathway were assessed by western blotting. The results of the present study demonstrated that treatment with IFN-γ increased miR-155-5p expression, in addition to inducing apoptosis and inflammation in SGECs. Furthermore, overexpression of miR-155-5p promoted IFN-γ-induced apoptosis and inflammation in SGECs. Overexpression of miR-155-5p also increased Bax protein expression, enzyme activities of caspase 3 and caspase 9, release of inflammatory cytokines interleukin-6 and tumor necrosis factor-α, and decreased Bcl-2 protein expression in IFN-γ-treated SGECs. By contrast, all of the effects aforementioned were reversed following miR-155-5p knockdown. These results demonstrated that miR-155-5p activated the NF-κB signaling pathway, where treatment with the NF-κB inhibitor, pyrrolidine dithiocarbamate, reversed the effects of miR-155-5p overexpression on the inflammatory factors in IFN-γ-induced SGECs. miR-155-5p was demonstrated to target ARRB2 and negatively regulated its expression levels, such that overexpression of ARRB2 reversed the effects of miR-155-5p overexpression on the inflammatory response, apoptosis and the NF-κB signaling pathway in IFN-γ-treated SGECs. Collectively, results from the present study suggest that miR-155-5p may activate the NF-κB signaling pathway by negatively regulating ARRB2 to promote salivary gland damage during SS pathogenesis. This suggests that miR-155-5p may serve to be a potential target for the treatment of SS.

Introduction

Sjögren’s syndrome (SS) is a common systemic autoimmune disease of exocrine glands, particularly the salivary glands (1). Dry mouth caused by salivary gland dysfunction is one of the typical features of SS (2). The pathogenesis and etiology of SS remain unclear, since complex elements, including genes and the environment, have been reported to contribute to the development of this disease (3,4). The inflammatory process of salivary glands is a common feature in patients with SS (5), where inflammation is associated with the persistence of interferon (IFN) signaling (6).

MicroRNAs (miRNAs/miRs) bind to target transcripts to suppress translation (7). Previous studies have demonstrated that miRNAs can regulate several biological processes, such as the innate immune response (8,9). miR-155-5p has multiple functions, including the regulation of tumor development (10), immune regulation (11) and oxidative stress (12). Furthermore, due to its notable regulatory effect on the immune system, miR-155-5p is closely associated with a variety of immune-related diseases (13,14), including during rheumatoid arthritis (15), systemic lupus erythematosus (16) and SS (2,17,18). It has been previously reported that miR-155-5p expression is markedly elevated in the peripheral mononuclear cells of patients with primary SS (19). However, the function of miR-155-5p in SS remains unclear, where its potential effect on salivary glands damaged by SS has not been reported previously.

ARRB2 is a scaffolding protein of the arrestin family, which exerts multiple functions, including promoting angiogenesis, alleviating neuropathic pain and modulating the sensitivity of cancer cells to chemotherapy drugs (20-22). Previous studies have demonstrated that ARRB2 also exhibits...
anti-inflammatory effects in some inflammatory diseases, such as colitis and sepsis (23-25). In addition, ARR2 has been reported to inhibit NF-κB signaling in septic and lipopolysaccharide-treated mice (23,26). Previous studies have demonstrated that NF-κB serve a promoting role in SS and its complications (27,28). Therefore, based on these previous findings aforementioned, the present study hypothesized that miR-155-5p may participate in SS-induced salivary gland damage by targeting ARR2.

Materials and methods

Isolation, transfection and treatment of salivary gland epithelial cells (SGECs). The present study was approved by the Ethics Committee of Hongki Hospital Affiliated to Mudanjiang Medical University (Mudanjiang, China) and performed in accordance with the Guidelines for the Care and Use of Laboratory Animals (29).

BALB/c mice, aged 7-8 weeks, weighted 20±2 g (n=30; 15 male and female) were purchased from Beijing Huafukang Biotechnology Co., Ltd. (http://www.hfkbio.com/). The housing conditions of the mice were: 12-h light/dark cycle, 25±1°C, and 45-55% humidity. All the mice were free access to food and water. Mice were euthanized by an intraperitoneal injection of sodium pentobarbital (200 mg/kg). In total, five mice were randomly selected from the 30 mice and the salivary glands were collected from the parotid, submandibular and sublingual glands. In accordance with previous research, SGECs were extracted from the salivary glands of five mice and pooled (30). Briefly, the salivary glands were washed 2-3 times with PBS. Tissue samples were minced into fragments (1-2 mm³) and cultured in a petri dish. Following incubation for 2 h at 37°C, DMEM/F12 complete medium (Procell Life Science & Technology Co., Ltd.) was added to the petri dish and the fragments were further incubated for 72 h at 37°C in 5% CO₂ and saturated humidity. The culture medium was replaced every 3 days until the cell density reached ~80%. The isolated SGECs were cultured in DMEM/nutrient mixture F-12 medium (Procell Life Science & Technology Co., Ltd.) supplemented with streptomycin (100 µg/ml), epidermal growth factor (10 ng/ml; Sino Biological), insulin (0.5 mg/ml; Shanghai Bying Biotechnology Co., Ltd.), hydrocortisone (0.4 mg/ml; Shanghai Aladdin Biochemical Technology Co., Ltd.) and FBS (3%; Biological Industries), at 37°C in 5% CO₂. SGECs were identified via immunocytochemistry staining of cytokeratin (CK) 7, CK8 and CK19 (31,32).

Transfection. Negative control (NC)/miR-155-5p agomir (25 nmol/l; Shanghai GenePharma Co., Ltd.) or NC/miR-155-5p antagomir (25 nmol/l; Shanghai GenePharma Co., Ltd.) were transfected into SGECs for 24 h at 37°C using Lipofectamine 2000 (5 µl; Invitrogen; Thermo Fisher Scientific, Inc.). Following incubation for 2 h at 37°C, DMEM/F12 complete medium (Procell Life Science & Technology Co., Ltd.) was added to the petri dish and the fragments were further incubated for 72 h at 37°C in 5% CO₂ and saturated humidity. The culture medium was replaced every 3 days until the cell density reached ~80%. The isolated SGECs were cultured in DMEM/nutrient mixture F-12 medium (Procell Life Science & Technology Co., Ltd.) supplemented with streptomycin (100 µg/ml), epidermal growth factor (10 ng/ml; Sino Biological), insulin (0.5 mg/ml; Shanghai Bying Biotechnology Co., Ltd.), hydrocortisone (0.4 mg/ml; Shanghai Aladdin Biochemical Technology Co., Ltd.) and FBS (3%; Biological Industries), at 37°C in 5% CO₂. SGECs were identified via immunocytochemistry staining of cytokeratin (CK) 7, CK8 and CK19 (31,32).

RT-qPCR. Total RNA was extracted from IFN-γ-treated SGECs using TRIpure reagent (cat. no. RP1001; BioTeke Corporation) and reverse transcribed into cDNA using M-MLV reverse transcriptase (cat. no. PR6502; BioTeke Corporation), dNTPs (Beijing Solarbio Science & Technology Co., Ltd.), and primers (Genscript, random hexamers and poly-A were used). The temperature protocol was used for reverse transcription for miR-155-5p: 37°C for 30 min, 42°C for 30 min and 70°C for 10 min. For interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), ARRB2 and β-actin, the thermocycling conditions were the following: Initial denaturation at 94°C for 10 min, 42°C for 50 min and 80°C for 10 min. The qPCR was performed using SYBR® Green I nucleic acid gel stain (cat. no. S9430; Sigma-Aldrich; Merck KGaA) and 2X Power Taq PCR Master Mix (cat. no. PR1702, BioTeke Corporation). The temperature protocol was used for qPCR for miR-155-5p: 37°C for 30 min, 42°C for 30 min and 70°C for 10 min. For interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), ARRB2 and β-actin, the thermocycling conditions were the following: Initial denaturation at 94°C for 5 min, followed by 40 cycles of 94°C for 15 sec, 60°C for 20 sec and 72°C for 15 sec. For IL-6, TNF-α, ARRB2 and β-actin, the thermocycling conditions were the following: Initial denaturation at 94°C for 5 min, followed by 40 cycles of 94°C for 15 sec, 60°C for 25 sec and 72°C for 30 sec. The following primer sequences were used for qPCR: miR-155-5p forward, 5'-TCA TGG CAT GAA AGA ATT -3'; miR-155-5p antagomir, 5'-ACC CCU AUC ACA ACC CAU UAA UU AGC AUU AA-3' and NC antagomir, 5'-CAG UAC UUU CUG UUG UUG UUG UUG-3'.
expression levels were calculated using the 2ΔΔCq method (33) and normalized to the internal reference gene β-actin. 5S rRNA served as the internal control for miRNA expression.

**Cell Counting Kit-8 (CCK-8) assay.** CCK-8 assay was performed to assess cell viability. SGCs were seeded into 96-well plates (3x10^4 cells each well). Following transfection for 24 h at 37°C, cells were incubated with CCK-8 solution for 1 h following the manufacturer's protocols at 37°C (10 µl each well; Sigma-Aldrich, Merck KGaA) before viability was subsequently analyzed at a wavelength of 450 nm, using a microplate reader.

**Apoptosis analysis.** Early and late apoptotic cells were assessed using flow cytometry. Cells were seeded into six-well plates at a density of 1x10^5 cells/well. Following transfection and treatment, apoptotic cells were analyzed. Briefly, cells in each group were collected and resuspended with 195 µl Annexin V-FITC (Beyotime Institute of Biotechnology). Cells (1x10^5) were subsequently treated with 5 µl Annexin V-FITC and 10 µl propidium iodide (both purchased from Beyotime Institute of Biotechnology) for 15 min at room temperature. Apoptotic cells were subsequently detected by flow cytometer (NovoCyte; ACEA Bioscience, Inc.) and analyzed by NovoExpress (version 1.2.5; ACEA Biosciences, Inc.).

**Immunofluorescence staining.** Cell slides were fixed with 4% paraformaldehyde for 15 min at room temperature and then incubated with 0.1% Triton X-100 for 30 min at room temperature. After blocking with 100% normal goat serum (Beijing Solarbio Science & Technology Co., Ltd.) for 15 min at room temperature, the cell slides were incubated with the anti-p65 antibody (1:200; total non-phosphorylated version; cat. no. sc-47778; Santa Cruz Biotech Co., Ltd.), Histone H3 (1:2,000; cat. no. AM8433; Abgent Inc.) and β-actin (1:1,000; cat. no. sc-47778; Santa Cruz Technology, Inc.) overnight at 4°C. Following primary antibody incubation, membranes were incubated with HRP-conjugated anti-rabbit/mouse IgG (1:5,000; cat. nos. A0208 and A0216; Beyotime Institute of Biotechnology) at room temperature for 20 min at 37°C. Proteins bands were visualized using an enhanced chemiluminescence reagent solution (Beyotime Institute of Biotechnology) and analyzed using a Gel-Pro-Analyzer (version 4.0; Beijing Liuyi Biotechnology, Inc.).

**Apoptosis analysis.** Following incubation for 48 h at 37°C, luciferase activities. After the cells were harvested and lysis, caspase-3 detection kit (cat. no. C1116; Beyotime Institute of Biotechnology) was used to detect caspase-3 activity in the lysates, whilst caspase-9 activity was measured using a caspase-9 detection kit (cat. no. BC3890; Beijing Solarbio Science & Technology Co., Ltd.). Caspase-3 and -9 activities were subsequently analyzed at a wavelength of 405 nm detected using a microplate reader (BioTek Instruments, Inc.).

**ELISA.** The ELISA kits (Wuhan Boster Biological Technology, Ltd.) were used to detect the expression levels of IL-6 (cat. no. EK0411) and TNF-α (cat. no. EK0527) in cell culture supernatant, according to the manufacturer's protocols. The optical density value was typed in and the 'submit' button was clicked. A number of genes potentially targeted by miR-155-5p can then be obtained. After searching for ARRB2, the 'Sites in UTR' button was clicked to obtain the targeted binding sequence of IL-6 (cat. no. EK0411) and TNF-α (cat. no. EK0527) in cell culture supernatant, according to the manufacturer's protocols.

**Western blotting.** Total protein was extracted using RIPA lysis buffer (Beyotime Institute of Biotechnology). Cytoplasmic protein and nuclear protein were extracted using a nuclear protein extraction kit (cat. no. P0027; Beyotime Institute of Biotechnology). Bicinchoninic acid protein assay kit was used to measure the protein concentration. Equal amounts of protein (20-40 µg) were separated via SDS-PAGE (10 and 12% gel). The separated proteins were subsequently transferred onto PVDF membranes (EMD Millipore) and blocked with 5% non-fat milk for 1 h at room temperature. The membranes were incubated with primary antibodies against Bcl-2 (1:1,000; cat. no. A19693; ABclonal Biotech Co., Ltd.), Bax (1:1,000; cat. no. A19684; ABclonal Biotech Co., Ltd.), Inhibitor of NF-κB (1:1,000; cat. no. A11397; ABclonal Biotech Co., Ltd.), phosphorylated (p)-IκB (1:1,000; cat. no. AP0707; ABclonal Biotech Co., Ltd.), NF-κB p65 (1:1,000; cat. no. AF5006; Affinity Biosciences), ARRB2 (1:1,000; cat. no. A1171; ABclonal Biotech Co., Ltd.), Histone H3 (1:2,000; cat. no. AM8433; Abgent Inc.) and β-actin (1:1,000; cat. no. sc-47778; Santa Cruz Technology, Inc.) overnight at 4°C. Following primary antibody incubation, membranes were incubated with HRP-conjugated anti-rabbit/mouse IgG (1:5,000; cat. nos. A0208 and A0216; Beyotime Institute of Biotechnology) at room temperature for 30 min. Proteins bands were visualized using an enhanced chemiluminescence reagent solution (Beyotime Institute of Biotechnology) and analyzed using a Gel-Pro-Analyzer (version 4.0; Beijing Liuyi Biotechnology, Inc.).

**Dual-luciferase reporter assay.** The binding sites between miR-155-5p and ARRB2 were predicted using TargetScan 7.2 (http://www.targetscan.org/vert_72). Briefly, the species was ‘Human’, following which the microRNA name ‘mir-155-5p’ was typed in and the ‘submit’ button was clicked. A number of genes potentially targeted by miR-155-5p can then be obtained. After searching for ARRB2, the ‘Sites in UTR’ button was clicked to obtain the targeted binding sequence between miR-155-5p and ARRB2. The association between miR-155-5p and ARRB2 was detected using dual-luciferase reporter assay. The mirGLO-ARRB2-3’-UTR-WT and pmirGLO-ARRB2-3’-UTR-MT plasmids were synthesized by GenScript. The plasmid (0.5 µg) and miR-155-5p mimic or its NC (25 pmol) were co-transfected into 293T cells at ~70%. The co-transfection was mediated by Lipofectamine® 3000 reagent (9 µl; Invitrogen; Thermo Fisher Scientific, Inc.). Following incubation for 48 h at 37°C, luciferase
miR-155-5p expression in IFN-γ-treated SGECs. SGECS were phenotyped by immunocytochemistry staining (Fig. 1A). The results demonstrated that the isolated cells exhibited strong cytokeratin expression, including that of epithelial markers CK7, CK8 and CK19, suggesting that the isolated cells were SGECs. RT-qPCR analysis demonstrated that miR-155-5p expression was significantly increased in SGECs following treatment with IFN-γ (Fig. 1B). Taken together, these results suggest that IFN-γ treatment increases miR-155-5p expression.

miR-155-5p promotes IFN-γ-induced apoptosis in SGECs. The effects of miR-155-5p knockdown and overexpression on the apoptosis of IFN-γ-treated SGECs were next assessed. RT-qPCR analysis demonstrated that miR-155-5p expression was significantly upregulated following transfection with miR-155-5p agomir, but was significantly downregulated following transfection with miR-155-5p antagonir compared with that in their corresponding NCs (Fig. 2A). Transfected SGECs were subsequently treated with IFN-γ (10 ng/ml) for 12 h. Treatment with IFN-γ significantly reduced cell viability and induced apoptosis in IFN-γ-treated SGECs, whereas miR-155-5p knockdown significantly increased cell viability and inhibited apoptosis compared with those in their corresponding NCs (Fig. 2B and C). Furthermore, treatment with IFN-γ significantly decreased Bcl-2 protein expression, but significantly increased Bax protein expression and the enzyme activity of caspase 3 and 9 in SGECs (Fig. 2D and E). Compared with those in their corresponding NCs, overexpression of miR-155-5p significantly potentiated the effect of IFN-γ on apoptotic protein expression and caspase 3 and 9 enzyme activity, whilst opposite effects were observed following the downregulation of miR-155-5p (Fig. 2D and E). Collectively, these results suggest that the overexpression of miR-155-5p aggravates IFN-γ-induced apoptosis, whereas miR-155-5p knockdown reversed IFN-γ-induced apoptosis in SGECs.

miR-155-5p promotes IFN-γ-induced inflammation in SGECs. The association between miR-155-5p and inflammation in IFN-γ-treated SGECs was assessed. Compared with those in control, treatment with IFN-γ significantly increased the mRNA expression levels of IL-6 and TNF-α in SGECs, which was significantly enhanced further following overexpression of miR-155-5p (Fig. 3A). By contrast, this phenomenon was reversed by miR-155-5p knockdown (Fig. 3A). Similar results were obtained according to results from ELISA (Fig. 3B). Taken together, these results suggest that overexpression of miR-155-5p may promote IFN-γ-induced inflammation, whilst miR-155-5p knockdown may alleviate IFN-γ-induced inflammation in SGECs.

miR-155-5p activates the NF-κB signaling pathway in IFN-γ-treated SGECs. The effects of miR-155-5p knockdown and overexpression on the NF-κB signaling pathway in IFN-γ-treated SGECs were next assessed. Western blot analysis demonstrated that the p-IκB/IκB ratio and the nuclear/cytoplasmic ratio of p65 were significantly increased following treatment with IFN-γ, which was significantly potentiated following the transfection with miR-155-5p.
agomir (Fig. 4A and B). By contrast, they were significantly reversed following transfection with miR-155-5p antagomir (Fig. 4A and B). Immunofluorescence staining demonstrated that the overexpression of miR-155-5p promoted the nuclear translocation of NF-κB p65 (total non-phosphorylated version) in IFN-γ-treated cells, whilst miR-155-5p knockdown resulted in the opposite effect being observed (Fig. 4C). Following the transfection with miR-155-5p agomir/agomir NC, SGECs were treated with IFN-γ (10 ng/ml) and PDTC (100 µM). The results demonstrated that the blockade of NF-κB signaling by PDTC significantly decreased the expression levels of IL-6 and TNF-α in miR-155-5p-overexpressed SGECs (Fig. 4D). Collectively, these results suggest that miR-155-5p overexpression aggravates IFN-γ-induced NF-κB signaling in SGECs.

ARRB2 is a downstream target gene of miR-155-5p. The binding sites of miR-155-5p on ARRB2 were predicted using TargetScan 7.2 (http://www.targetscan.org/vert_72), where miR-155-5p was predicted to target ARRB2 directly (Fig. 5A). Dual-luciferase reporter assay results showed that luciferase activity in miR-155-5p agomir + WT 3'UTR group was significantly decreased compared with that in the miR-155-5p agomir + MT 3'UTR and Agomir NC + WT 3'UTR groups (Fig. 5A). The association between miR-155-5p expression and ARRB2 was subsequently assessed. The results demonstrated that ARRB2 mRNA and protein expression levels were significantly inhibited in IFN-γ-treated SGECs following transfection with miR-155-5p agomir compared with those in IFN-γ-treated cells transfected with NC agomir (Fig. 5B and C). Conversely, ARRB2 mRNA and protein expression levels were significantly elevated in IFN-γ-treated SGECs following transfection with miR-155-5p antagonist compared with those in IFN-γ-treated cells transfected with NC antagonist (Fig. 5B and C). Subsequently, the ARRB2 overexpression plasmid and miR-155-5p agomir were co-transfected into SGECs before IFN-γ (10 ng/ml) was used to treat the transfected cells for 12 h. The transfection efficiency of the ARRB2 plasmid into SGECs was first verified by western blotting (Fig. 5D). In the presence of both IFN-γ and miR-155-5p mimics, overexpression of ARRB2 significantly reduced the expression levels of IL-6 and TNF-α (Fig. 5E). In addition, the overexpression of ARRB2 significantly suppressed the miR-155-5p overexpression-induced apoptosis in IFN-γ-treated SGECs (Fig. 5G). Translocation of NF-κB p65 from the cytoplasm to the nucleus, which was
observed to be induced by the overexpression of miR-155-5p, was also significantly abrogated following the overexpression of ARRB2 in IFN-γ-treated SGECs (Fig. 5F). Taken together, these results suggest that ARRB2 may partially or completely mediate the effects of miR-155-5p on inflammation and apoptosis in IFN-γ-treated SGECs.

**Discussion**

The results of the present study demonstrated that treatment with IFN-γ increased miR-155-5p expression, such that apoptosis and inflammation in IFN-γ-treated SGECs may be induced by this increased miR-155-5p expression. Furthermore, it was demonstrated that miR-155-5p may activate NF-κB signaling by negatively regulating ARRB2, thereby promoting salivary gland damage in SS.

SS is an autoimmune disease, particularly in the exocrine glands, such as salivary and lacrimal glands (34). However, the pathogenesis of SS remains unclear. Therefore, it is necessary to study the pathogenesis of SS and its potential therapeutic targets. It has been previously demonstrated that miRNAs can regulate immune responses, including infection and autoimmunity (35,36). Previous studies have also reported that miR-155-5p exerts an important regulatory role in the generation of humoral and cellular immune responses during infection and autoimmunity (37,38).

Salivary gland damage is a common clinical symptom of SS (39). Previous studies have demonstrated that patients with SS and animal models of SS exhibit secretory dysfunction, particularly in the salivary gland epithelium (40,41). In addition, inflammation and apoptosis of SGECs have also been reported to be a possible mechanism for impaired secretory function (42).
Release of proinflammatory cytokines, including TNF-α and IFN-γ, in the exocrine glands of patients with SS and apoptosis of SGECs significantly increases (43,44). The present study investigated the effects of miR-155-5p on the apoptosis and inflammation in SGECs. Previous studies have demonstrated that miR-155-5p expression is positively associated with primary SS (19). High levels of miR-155-5p have also been reported in inflammatory lesion models, such as cerebral
ischemia-reperfusion injury (45). As previously reported, an inflammatory lesion model was established in SGECs by treatment with IFN-γ, where IFN-γ-treatment increased apoptosis and IL-6 and TNF-α mRNA expression (30). Results from the present study demonstrated that miR-155-5p overexpression promoted IFN-γ-induced apoptosis in SGECs, since cell viability was decreased and the apoptotic rate was increased, in addition to the increased expression levels of...
apoptosis-related proteins in miR-155-5p overexpressing cells. These results also demonstrated that miR-155-5p overexpression promoted IFN-γ-induced inflammation, which was evidenced by the increased IL-6 and TNF-α levels in miR-155-5p overexpressing cells. Overall, these results suggest that miR-155-5p may exert a role in salivary gland damage during SS by promoting the inflammatory response and apoptosis of SGECs.

NF-κB is chronically active in several inflammatory autoimmune diseases, including inflammatory bowel disease (46), rheumatoid arthritis (47) and SS (48). Sisto et al (49) demonstrated that the NF-κB signaling pathway is activated in human SGECs derived from active primary patients with SS. Lisi et al (50) reported that activation of NF-κB signaling is a potentially important mechanism for SS development. Furthermore, it has been demonstrated that dysregulation of NF-κB in glandular epithelial cells results in Sjogren's-like features (51). Activation of NF-κB signaling promotes inflammation and induces apoptosis of human SGECs in primary SS (52). Proinflammatory cytokines, such as IFN-γ, activate the IκB kinase complex, which phosphorylates IκB and targets it for proteasomal degradation (53). This releases NF-κB which, after phosphorylation, allows it to translocate into the nucleus (53). NF-κB either acts alone in the nucleus or with other transcription factors to induce target gene expression (53). The results of the present study demonstrated that the phosphorylation levels of IκB and the nuclear translocation of p65 were increased, suggesting that miR-155-5p activates NF-κB signaling. Taken together, these results suggest that miR-155-5p may promote salivary gland damage in SS by regulating the NF-κB signaling pathway.

ARRB2 is a downstream target gene of miR-155-5p (54). The results of the present study verified this association. Li et al (55) demonstrated that the overexpression of ARRB2 may inhibit the release of proinflammatory cytokines and decrease experimental arthritis severity. In addition, ARRB2 has exhibited antiapoptotic effects in human endometrial cancer heterotransplants in nude mice (56,57). The results of the present study demonstrated that overexpression of ARRB2 reversed the effects of miR-155-5p overexpression on the inflammatory response, apoptosis and the NF-κB signaling pathway in this inflammatory lesion model. ARRB2 has been previously reported to inhibit the NF-κB signaling pathway in a sepsis mouse model and LPS-induced liver injury (23,26). Collectively, these results suggest that miR-155-5p may promote salivary gland damage in SS by negatively regulating ARRB2, thereby promoting salivary gland damage of SS. The results of the present study verified the role and the potential molecular mechanism of miR-155-5p in salivary gland damage in SS, suggesting that miR-155-5p may serve to be a potential target for SS treatment.

Acknowledgements
Not applicable.

Funding
This study was supported by a grant from the Fundamental Research Business Expense of Universities in Heilongjiang Province (grant no. 2018-KYYWFMY-0060).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
JLZ and HZZ designed the study and wrote the manuscript. LLZ and HS performed the experiments, confirmed the authenticity of all the raw data and conducted statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The present study was approved by the Ethics Committee of Hongqi Hospital Affiliated to Mudanjiang Medical University (Mudanjiang, China).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Baldini C, Talarico R, Tzioufas AG and Bombardieri S: Classification criteria for Sjögren's syndrome: A critical review. J Autoimmun 39: 9-14, 2012.
2. Reale M, D'Angelo C, Costantini E, Laus M, Moretti A and Croce A: MicroRNA in Sjögren's syndrome: Their potential roles in pathogenesis and diagnosis. J Immunol Res 2018: 7510174, 2018.
3. Ramos-Casals M, Tzioufas AG and Font J: Primary Sjögren's syndrome: New clinical and therapeutic concepts. Ann Rheum Dis 64: 347-354, 2005.
4. Jimenez SA and Piera-Velazquez S: Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome. Autoimmun Rev 12: 1046-1051, 2013.
5. Saito M, Ota Y, Ohashi H, Dei Y, Shimoyama K, Suzuki D, Hayashi H and Ogawa N: CD40-CD40 ligand signal induces the intercellular adhesion molecule-1 expression through nuclear factor-kappa B p50 in cultured salivary gland epithelial cells from patients with Sjögren's syndrome. Mod Rheumatol 17: 45-53, 2007.
6. Gottenberg JE, Cagnard N, Lucchesi C, Letourneau F, Mistou S, Lazure T, Jacques S, Ba N, Itah M, Lepajolec C, et al.: Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc Natl Acad Sci USA 103: 2770‑2775, 2006.

7. Bushati N and Cohen SM: MicroRNA functions. Annu Rev Cell Dev Biol 23: 175‑205, 2007.

8. Chen CZ, Li L, Lodish HF and Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 1532‑1536, 2004.

9. Mestdagh E, Feyes T, Bernard N, Guenther S, Chen C, Speleman F and Vandesoempel J: High-throughput stem-loop RT‑qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 36: e143, 2008.

10. Wang X, Huang G, Mu J, Cong Z, Chen S, Fu D, Qi J and Sun F: miR‑155‑5p inhibits PD1 and promotes autophagy via the mTOR pathway in cervical cancer. Int J Biochemistry Cell Biol 99: 91‑99, 2018.

11. Elton TS, Selemon H, Elton SM and Parinandi NL: Regulation of the MIR155 host gene in physiological and pathological processes. Gene 523: 1‑12, 2016.

12. Jiang K, Hu J, Luo G, Song D, Zhang P, Zhu J and Sun F: miR‑155‑5p promotes oxalate‑ and calcium‑induced kidney oxidative stress injury by suppressing MGP expression. J Cell Mol Med 2019: 5863617, 2020.

13. Goncalves‑Alves E, Saferding V, Schliehe C, Benson R, Kühler K, Elson M, Tüting T: Gene dosage‑dependent negative regulatory role of β‑arrestin‑2 attenuates lipopolysaccharide‑induced liver injury via inhibition of TLR4/NF‑κB activation. J Autoimmun 86: 62‑74, 2018.

14. Vigorito E, Kohlhaas S, Lu D and Leyland R: miR‑155: an ancient regulator of the immune system. Immun Rev 235: 146‑157, 2013.

15. Tavosifian F, Abdollahi E, Rezaei R, Monttazi‑Boroojeni AA, Henrotin Y and Sahebkar A: Altered expression of microRNAs in rheumatoid arthritis. J Cell Biochem 119: 478‑487, 2018.

16. Gao W, Quan G, Luo W, Liu X, Pei H, Han L, Yuan L, A X and Deng D: miR‑125b is downregulated in systemic lupus in patients with Sjögren’s syndrome. Proc Natl Acad Sci USA 106: 2735‑2740, 2009.

17. Johansson A, Nyberg WX, Sjöstrand M, Moruzzi N, Bergman P, Khademi M, Andersson M, Piehl F, Lena RN, Jonsson R, Mariette X, Sivilis K, Theander E, Tzioufas A and Ramos‑Casals M: Sjögren syndrome. Nat Rev Dis Primers 2: 16047, 2016.

18. Mehta A and Baltimore D: MicroRNAs as regulatory elements in immune system. Nat Rev Immunol 16: 279‑294, 2016.

19. Routar T, Tammes‑Rad M, 47: 2473‑2483, 2019: Anti‑inflammatory microRNA and their potential for inflammatory diseases treatment. Front Immunol 9: 1377, 2018.

20. Ceppi M, Pereira PM, Dunand‑Sauthier I, Barras E, Reith W, Santos MA and Pierre P: MicroRNA‑155 modulates the interleukin‑1 signaling pathway in activated human monocyte‑derived dendritic cells. Proc Natl Acad Sci USA 106: 2735‑2740, 2009.

21. Kurowska‑Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, Reilly J, Imera M, Fraser AR, Stolarski B, et al.: MicroRNA‑155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA 108: 11193‑11198, 2011.

22. Milic V, Colic J, Cirkovic A, Stanovljevic S and Damjanov N: Disease activity and damage in patients with primary Sjögren’s syndrome: Prognostic value of salivary gland ultrasonography. J Oral Pathol Med 48: e64988, 2019.

23. Daniels TE, Silverman S Jr, Michalski J, Maladeck J, Chang Y, Li J and Gu Z: B7‑H3 participates in human salivary gland epithelial progenitor cells in liver regeneration. Sci Rep 7: 12077, 2017.

24. Gao Y, Li M, Chen S, Li G and Ji Y: Isolation, culture and phenotypic characterization of human sweat gland epithelial cells. Int J Mol Med 34: 867‑874, 2014.

25. Wang X, Huang G, Mu J, Cong Z, Chen S, Fu D, Qi J and Li Z: Arbr2 promotes endothelial progenitor cell‑mediated postischemic neovascularization. Theranostics 10: 9899‑9920, 2020.

26. Chen G, Xie XG, Gao YJ, Xu ZZ, Zhao X, Bang S, Berta T, Park CK, Lay M, Chen W and Ji RR: β‑arrestin‑2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain. J Invest Dermatol 134: 2131‑2137, 2014.

27. Shi Y, Li K, Xu K and Liu QH: miR‑155‑5p accelerates symptomatology‑in‑targeting NOD Idd‑associated intervals in primary Sjögren’s syndrome. J Transl Med 17: 268, 2019.

28. Baker OJ, Camden JM, Redman RS, Jones JE, Seye CI, Erb L and Weisman GA: Proinflammatory cytokines tumor necrosis factor‑alpha and interferon‑gamma alter tight junction structure and function in the rat small intestinal crypt‑‑‑‑type cell line. Am J Physiol Cell Physiol 295: C1191‑C1201, 2008.

29. Roman‑Blas JA and Jimenez SA: NF‑κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 14: 839‑848, 2006.

30. Sisto S, Muto R, Napolitano A, Scorcia F, Scagliusi V, D’Amore M, Maffione AM and Mitolo V: Fcγreceptors mediate internalization and degradation of anti‑IgA antibodies from Sjögren’s syndrome and apoptosis in human salivary gland cell line A253. J Oral Pathol Med 36: 511‑523, 2007.
49. Sisto M, Lisi S, Lofrumento DD, Ingravallo G, Maiorano E and D’Amore M: A failure of TNFAIP3 negative regulation maintains sustained NF-κB activation in Sjögren’s syndrome. Histochem Cell Biol 135: 615-625, 2011.

50. Lisi S, Sisto M, Lofrumento DD and D’Amore M: Sjögren’s syndrome autoantibodies provoke changes in gene expression profiles of inflammatory cytokines triggering a pathway involving TACE/NF-κB. Lab Invest 92: 615-624, 2012.

51. Wang X, Shaalan A, Liefers S, Coudenys J, Elewaut D, Proctor GB, Bootsma H, Kroese FGM and Pringle S: Dysregulation of NF-kB in glandular epithelial cells results in Sjögren’s-like features. PLoS One 13: e0200212, 2018.

52. Sisto M, Lorusso L and Lisi S: TLR2 signals via NF-κB to drive IL-15 production in salivary gland epithelial cells derived from patients with primary Sjögren’s syndrome. Clin Exp Med 17: 341-350, 2017.

53. Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1: a001651, 2009.

54. Zhou Y, Song Y, Shaikh Z, Li H, Zhang H, Caudle Y, Zheng S, Yan H, Hu D, Stuart C and Yin D: MicroRNA-155 attenuates late sepsis-induced cardiac dysfunction through JNK and β-arrestin 2. Oncotarget 8: 47317-47329, 2017.

55. Li P, Cook JA, Gilkeson GS, Luttrell LM, Wang L, Borg KT, Halushka PV and Fan H: Increased expression of beta-arrestin 1 and 2 in murine models of rheumatoid arthritis: Isoform specific regulation of inflammation. Mol Immunol 49: 64-74, 2011.

56. Hong F, Zhang Y, Cheng W, Sun X and Wang J: β-arrestin-2 up-regulates toll-like receptor 2 signaling and inhibits apoptosis in human endometrial cancer heterotransplants in nude mice. BMC Cancer 19: 1035, 2019.

57. Li Y, Sun X, Zhang Y, Huang J, Hanley G, Ferslew KE, Peng Y and Yin D: Morphine promotes apoptosis via TLR2, and this is negatively regulated by beta-arrestin 2. Biochem Biophys Res Commun 378: 857-861, 2009.

58. Trotta R, Chen L, Ciurlario D, Jiosyula S, Mao C, Costinean S, Yu L, Butchar JP, Trindandapani S, Croce CM and Caligiuri MA: miR-155 regulates IFN-γ production in natural killer cells. Blood 119: 3478-3485, 2012.

59. Yee D, Shah KM, Coles MC, Sharp TV and Lagos D: MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J Biol Chem 292: 20683-20693, 2017.

60. Kim JH, Jou I and Joe EH: Suppression of miR-155 expression in IFN-γ-treated astrocytes and microglia by DJ-1: A possible mechanism for maintaining SOCS1 expression. Exp Neurobiol 23: 148-154, 2014.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.